Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.

Last updated on 23-8-2019 by Anonymous (not verified)

Peer reviewed scientific article

English

SCIENSANO

Keywords

Abstract:

BACKGROUND: Prevalence data of chronic hepatitis C virus (HCV) infection are needed to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAAs). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% from 1993 to 1994. In this first Belgian nationwide HCV prevalence study, we set out to update the seroprevalence and prevalence of chronic HCV infection estimates in the Belgian general population in order to guide decisions on DAA reimbursement. METHODS: Residual sera were collected through clinical laborat…

Associated health topics:

QR code

QR code for this page URL